BriaCell Therapeutics Corporation (BCTX) Quote

BriaCell’s cancer vaccine platform offers strong synergy with checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 therapies.

BriaCell $BCTX is hosting two virtual investor presentations this June:

June 12 at 12 PM EDT
June 26 at 12 PM EDT

To Learn more about their cancer immunotherapy pipeline and clinical progress.
Click here: https://www.globenewswire.com/news-release/2025/06/04/3093465/0/en/BriaCell-Announces-Virtual-Investor-Presentations-on-Thursday-June-12-and-Thursday-June-26.html

$BCTX News Out - BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)
Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients in the literature
Meaningful Clinical Benefit observed in all MBC subtypes, including HER2+, HR+/HER2-, and triple-negative breast cancer (TNBC)
Overall survival and clinical benefit data reported meets or exceeds that of FDA-approved therapies in comparable patients
No treatment-related discontinuations

PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study (ClinicalTrials.gov identifier: NCT06072612), and Phase 1/2 study of Bria-OTS (ClinicalTrials.gov identifier: NCT06471673) in metastatic breast cancer.

“Prolonging survival and providing meaningful clinical benefit for patients whose disease has demonstrated resistance to multiple treatment options remains a critical unmet need in breast cancer. These Bria-IMT regimen results are promising for individuals with metastatic breast cancer,” said Sara A. Hurvitz, MD, FACP, Senior Vice President, Director of the Clinical Research Division, and Smith Family Endowed Chair in Women’s Health at Fred Hutch Cancer Center, as well as Professor and Head of the Division of Hematology and Oncology at the University of Washington, Seattle, WA, and co-author of one of the clinical posters. “The low incidence of all grade and grade 3/4 adverse events is particularly notable.”

“We are thrilled with our Phase 2 overall survival and clinical benefit data which meets and exceeds those of FDA approved drugs — even in very heavily pre-treated patients in our study,” noted Dr. William V. Williams, BriaCell’s President & CEO. “We look forward to further confirming these impressive results in our ongoing pivotal Phase 3 study with the ultimate goal of bringing novel treatments to cancer patients in need.”

The details of the poster presentation sessions and publish-only abstract are listed below.

Poster Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
Session Date and Time: June 2, 2025 9:00 AM-12:00 PM CDT
Abstract Number for Publication: TPS1138
Poster Board Number: 108a
Session Type and Title: Poster Session – Breast Cancer—Metastatic

“Trial in Progress” poster presents early enrollment data and the overall design of the Phase 3 pivotal trial along with updated clinical outcomes from the Phase 2 Bria-IMT study.

Poster Title: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer
Session Date and Time: June 2, 2025 9:00 AM-12:00 PM CDT
Abstract Number for Publication: 1096
Poster Board Number: 75
Session Type and Title: Poster Session – Breast Cancer—Metastatic

In the Phase 2 study of Bria-IMT combined with an immune checkpoint inhibitor (CPI) in 54 heavily pre-treated metastatic breast cancer (MBC) patients (median of six prior systemic therapies; range 2–13), Bria-IMT demonstrated promising efficacy and safety. Notably, 44% of patients had failed a prior antibody-drug conjugate, and 20% had failed a prior CPI. Among these patients, the overall clinical benefit rate (CBR; defined as CR, PR, or SD) was 55%, with CBRs of 100% in HER2+, 55% in HR+/HER2-, and 45% in triple-negative breast cancer (TNBC) subgroups, indicating antitumor activity across MBC subtypes. Additionally, patients treated with the selected Phase 3 formulation (without IFN?; N=37) experienced significantly improved overall survival (13.9 vs. 6.93 months; P=0.01) compared to those receiving the alternate formulation, highlighting the potential of Bria-IMT for advancing in clinical development.

Read more here : https://www.globenewswire.com/news-release/2025/06/02/3091756/0/en/BriaCell-Reports-Robust-Overall-Survival-and-Clinical-Benefit-Data-at-ASCO-2025.html

$BCTX clears safety milestone in Bria-OTS™ Phase 1/2 study and doses first patient in CPI combo arm for metastatic breast cancer. Monotherapy patient shows complete lung metastasis resolution. Major step toward personalized cancer care. Read: https://globenewswire.com/news-release/2025/05/27/3088507/0/en/BriaCell-Bria-OTS-Phase-1-2-Study-Clears-Safety-Evaluation-Doses-First-Patient-in-Combination-with-Checkpoint-Inhibitor.html

$BCTX “…marks a significant milestone for BriaCell,” Doses First Patient in Combination with Checkpoint Inhibitor. Application across multiple cancer types including breast and prostate cancers.

READ: https://finance.yahoo.com/news/briacell-bria-ots-phase-1-113000501.html

What a bitch these shorts are

if it opens at these levels I'll add... and I'll gladly hold on until the end of phase 3 and beyond!

Wow, what volumes!

BriaCell has just presented highly encouraging data at ASCO 2025: their Phase 2 results with Bria-IMT™ + checkpoint inhibitor in metastatic breast cancer match or exceed the outcomes of FDA-approved therapies — despite being tested in a more heavily pre-treated population.
Notably, the selected Phase 3 regimen showed a median overall survival of 13.4 months and clinical benefit rate of 61%, outperforming several standard-of-care arms in benchmark studies like ASCENT and TROPiCS-02. Even more compelling: no treatment-related discontinuations were reported.
These results strongly support Bria-IMT’s safety and efficacy, positioning the ongoing pivotal Phase 3 study as a potential pathway to Biologics License Application (BLA) submission with the possibility of Priority Review…

from 9.9% to 4.9%, holding 190,006 common shares.
holds 98,311 warrants to purchase common shares. However, the exercise of these warrants is subject to a 4.99% ownership limitation ("blocker"), preventing the holder from exceeding this threshold without prior adjustment.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319163389&type=HTML&symbol=BCTX&cdn=4fd3b05ac8453fea46587e9835855dd1&companyName=BriaCell+Therapeutics+Corp.&formType=SCHEDULE+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2025-05-13

CVI Investments, Inc., managed by Heights Capital Management, Inc., filed a Schedule 13G disclosing a passive ownership of 489,200 common shares of BriaCell Therapeutics Corp., representing approximately 8.6% of the company’s outstanding shares as of April 24, 2025.

This stake likely originates from participation in BriaCell’s public offering announced on April 24, 2025, which involved 3,066,666 units (each consisting of a common share or prefunded warrant and one warrant with a $5.25 exercise price).
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319127530&type=HTML&symbol=BCTX&cdn=69d3e85b7de2a0c92a3ec26bb9949c5d&companyName=BriaCell+Therapeutics+Corp.&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2025-05-01

$BCTX shares major progress in its shareholder letter:

✅Repeated DSMB praise for Phase 3 Bria-IMT study

✅Fast Track status + accelerated enrollment

✅Phase 2 survival data outperforming standard of care

https://globenewswire.com/news-release/2025/05/20/3084743/0/en/BriaCell-CEO-Letter-to-Shareholders.html

MC 12,5 Mil
You see a flower? I see a future blockbuster that just needs the right value to grow on its own – it can buy its own flowers!

BriaCell hits the Fast Track!
The CEO’s letter is full of good news, but one shines above the rest:
Bria-IMT has received FDA Fast Track designation!
Canadian or not… when a tumor vanishes, science wins!
Plus:
• Phase 3 trial is enrolling well, with repeated green lights from the DSMB
• Phase 2 data: outperforming TRODELVY in HR+ patients
• Bria-OTS platform made a metastasis disappear – seriously impressive!
With $13.8 million raised and ASCO coming up…

BCTX, new 52 week low

Briacell is scheduled to present tomorrow and Wednesday.$BCTX

These guys do multiple offerings on news. They are notorious for this. Be careful. I have shares not shorting it. Just fyi. GL to all.$BCTX 

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™


https://www.biospace.com/press-releases/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots

wow! This is pathetic

Most likely. These Biotechs burn ridiculous amounts of cash on FDA studies.

they selling shares on the news? should easily be above 10+

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast cancer patient
Treatment well-tolerated and patient remains on study with stable disease elsewhere
Sustained clinical response supports Bria-OTS personalized, off-the-shelf immunotherapy approach in Phase 1/2a metastatic breast cancer study
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four months also demonstrates stable disease elsewhere.

Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4 months of therapy1 (axial and coronal views)

https://ml.globenewswire.com/Resource/Download/19a24c7d-e793-4f57-b0df-c1605b7395dc/briacell-figure-1.png

As shown, the lesion in the patient’s right lung is undetectable after two months and confirmed resolved at 4 months. The updated images supersede those previously reported.

The patient, a 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative), had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study. At enrollment on November 21, 2024, she had extensive metastases including bone, lymph node and lung involvement. Following Bria-OTS intradermal injections every 2 weeks for six weeks (4 total doses), and subsequent dosing every 3 weeks, the lung metastasis completely resolved with stable disease elsewhere. This response is now confirmed and shows the potentially promising activity of the Bria-OTS platform as monotherapy.

“Despite recent advancements with Antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), many patients, including those with HR+ disease, like BriaCell’s first OTS patient, have very few options,” stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, Ca., and Principal Investigator for the Bria-OTS study. “We are thrilled with our initial data with single agent Bria-OTS showing rapid and strong anti-tumor activity in an HR+ patient and look forward to continuing this novel approach in patients with MBC, and other cancers.”

“This unprecedented anti-cancer response in the first patient dosed with Bria-OTS is an important milestone for us and provides early validation of BriaCell’s personalized immunotherapy approach,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Bria-OTS is a personalized off-the-shelf immunotherapy, currently under investigation in a Phase 1/2a dose escalation study (ClinicalTrials.gov identifier: NCT06471673) in metastatic recurrent breast cancer. Bria-OTS represents a personalized, next generation, advancement of BriaCell’s lead candidate Bria-IMT™ which is currently in a pivotal Phase 3 study for metastatic breast cancer. The Phase 1/2a clinical trial in metastatic breast cancer is a dose escalation study initially evaluating the safety and efficacy of Bria-OTS as monotherapy and will be followed by Bria-OTS in combination with an immune checkpoint inhibitor.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements,

BCTX..................................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

Trader Alert: Potential Breakout Candidate Issues Big Cancer News! $BCTX is speeding up enrollment in its Phase 3 trial for metastatic breast cancer.

75+ patients enrolled across 54 sites.

Top-line data could come as early as H1 2026.

More details here: https://finance.yahoo.com/news/briacell-enrollment-pace-accelerating-phase-113000724.html

$BCTX In the spotlight the week of 28April
https://www.abstractsonline.com/pp8/#!/20273/presentation/8077

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patients
Survival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY®
No Bria-IMT related discontinuations reported to date https://www.otcmarkets.com/stock/BCTX/news/story?e&id=3211304

BCTX.............................................................p/m

BCTX: Roger that, Capt.!!

$3.83 + 10% Super low float power 3.33 52 week low ...on watch add a few for now 

priced a best-efforts public offering of 762,500 common shares at $4.00 per share, with expected gross proceeds of $3.05 million before fees and expenses.

Hahahaha 🤣😂

BCTX: I.e., where their 'Investigational Drug Group' consisted of 400-PATIENTS --- vs. merely just ONE, as in their bogus PR today!!!

BCTX: Could you imagine where the PRICE of this stock would be right now, if this Firm had PR'd legitimate STATISTICS to the effect that 75% of the 'Investigational Drug Group' enjoyed 100% remission of their metastasized LUNG CANCERS --- when compared to the 'Placebo Group", & all other 'Control Groups' & 'Standard of Care Groups'??? (And moreover, this HOAX Company did NOT even entertain ANY 'Control Groups', nor 'Standard of Care Groups', AT ALL!!! Their only experimental 'competition', as it were, was a useless 'PLACEBO GROUP'!!! I myself KNOW this stuff, Peeps!!! Anyone who got suckered by the conspicuous NONSENSE within BCTX's PR today, is patently-STUPID --- even when compared to all universal, 'Standards of Stupidity!!!)


"Tell-it-like-it-is, Oh Great Invest-in-America, Dude!!! You're doing GOD's work, Homeboy!!!"
/////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

BCTX: At least I can recognized a HOAX, when I see one!! (And they even PR'd a cute 'X-RAY' too, of a TINY SPOT of purported metastasized CANCER that had suddenly disappeared behind their disruptive new ELIXIR!!!)

THE BIO BEAST OF THE DAY...DILUTION WILL KICK IN NOW

One patient all it takes $6.75 .. .."That's one small step for man, one giant leap for mankind." However, Armstrong insisted that he actually said, "That's one small step for a man," though the "a" was not clearly heard in the transmission...

BCTX: Straight-up HOAX!!! (Such a PR is never, never, never DONE behind one patient!!!)

BCTX........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

does seem questionable -- certainly a very impressive result -- but one person only --- abberations do occur

BCTX: Their purported NEWS is a "Statistical Artifact" --- significant of NOTHING!!! No legitimate Pharma firm would ever PR such (One Patient) crap!!!

I'm seeing 2.7m float

BCTX: Something very CREEPY here, Peeps!!! (Be careful!!)

huge news-Treatment with Bria-OTS™ monotherapy resulted in 100% resolution of tumor in the lung of the MBC patient following 4 injection cycles


This 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative) had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS™ study. At enrollment on Nov 21, 2024, she had extensive metastases including multiple bone, lymph node and lung metastases. Following 4 injections with Bria-OTS™ every 2 weeks, the lung metastasis completely resolved, and she had stable disease elsewhere.

https://feeds.issuerdirect.com/news-release.html?newsid=7417246418288908

BCTX: One patient cured. (Warrants here??)

BCTX $5.90 + 16% 20m floater but news is decent..

BCTX POST SPLIT RUN UNDERWAY

BCTX, new 52 week low

BCTX: It's actually GREEN now in price!!! (Heck, maybe there IS a "God" --- of WOMEN, hopefully!!!! And NOT some clown nailed to a cross in Naples, Italy, 2K years ago!!!!)

BCTX: I sincerely HOPE that this BCTX stock --- with GREAT news for Women's BREAST Cancer concerns --- gets monster short-SQUEEZED, like below!!! Metaphorically speaking, that is.)

Slow and Steady up

BCTX: The Markets simply do NOT give-a-fluck about WOMEN's issues of any sort!!! (BCTX could have PR'd that they have outright CURED all Breast Cancers, but this stock STILL would not have soared in price!!!)